Open AccessCost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran
Author(s) -
Khadijeh Ezoji,
Mohsen Yaghoubi,
Marzieh Nojomi,
Sussan Mahmoody,
Seyed Mohsen Zahraie,
Maziar MoradiLakeh,
Sedigheh Rafiee Tabatabaei,
Abdollah Karimi
Publication year - 2019
Publication title -
eastern mediterranean health journal/eastern mediterranean health journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 47
eISSN - 1687-1634
pISSN - 1020-3397
DOI - 10.26719/emhj.19.039
Subject(s) - medicine , meningitis , pneumonia , streptococcus pneumoniae , pneumococcal conjugate vaccine , pediatrics , vaccination , otitis , pneumococcal infections , pneumococcal vaccine , intensive care medicine , immunology , antibiotics , surgery , microbiology and biotechnology , biology
Pneumococcal disease caused by Streptococcus pneumoniae results in considerable mortality and morbidity. Pneumococcal conjugate vaccines (PCV), such as PCV-13, can prevent invasive pneumococcal disease and avoid disability and death. The cost of introducing PCV-13 in childhood immunization schedules should be assessed against the cost of pneumococcal diseases for each community.